EU Approves Fifth Copy of AbbVie ' s $18 Bln Drug Humira EU Approves Fifth Copy of AbbVie ' s $18 Bln Drug Humira

Europe has approved a fifth copy of AbbVie ' s $18-billion-a-year biologic drug Humira (adalimumab) – the world ' s best-selling prescription medicine – ramping up competition among makers of less-expensive biotech drugs.International Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Rheumatology News Alert Source Type: news